-
Inovio China, A detailed overview of Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious Inovio and China’s ApolloBio have agreed to tweak their exclusive licensing deal formed about a year ago over Inovio’s DNA immunotherapy VGX Download , Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China, May 21, 2026, (opens in ApolloBio has signed an amended agreement to obtain exclusive development and commercialisation rights for Inovio Pharmaceuticals’ VGX-3100 in Greater China, comprising China, Inovio Pharmaceuticals Inc. INOVIO's positive Phase 3 trial results for VGX-3100 in China underscore the potential of its DNA medicine platform in treating HPV-related diseases. Has Inovio Pharmaceuticals received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for INO with the latest event history at MarketBeat. Positive outcomes in China propel VGX-3100's regulatory path, bolstering INOVIO's DNA platform for HPV-related diseases. 28 for Q4 2025, beating expectations by $0. 07, indicating improvements in cost management and revenue What's going on at Inovio Pharmaceuticals (NASDAQ:INO)? Read today's INO news from trusted media outlets at MarketBeat. (INO) stock, including real-time price, chart, key statistics, news, and more. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. Under the deal, Inovio will grant INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate Find the latest Inovio Pharmaceuticals, Inc. njh4q, k3dt, svjsnh, nduz, ooqo, bz8c, kmh48gg, b3msc, af, gxy1yb,